Cargando…
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
BACKGROUND: Therapies may be more efficacious when targeting a patient subpopulation with specific attributes, thereby enhancing the cost-effectiveness of treatment. In the CRYSTAL study, patients with metastatic colorectal cancer (mCRC) were treated with cetuximab plus FOLFIRI or FOLFIRI alone unti...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028886/ https://www.ncbi.nlm.nih.gov/pubmed/29948926 http://dx.doi.org/10.1007/s40258-018-0395-5 |
_version_ | 1783336861692854272 |
---|---|
author | Harty, Gerard Jarrett, James Jofre-Bonet, Mireia |
author_facet | Harty, Gerard Jarrett, James Jofre-Bonet, Mireia |
author_sort | Harty, Gerard |
collection | PubMed |
description | BACKGROUND: Therapies may be more efficacious when targeting a patient subpopulation with specific attributes, thereby enhancing the cost-effectiveness of treatment. In the CRYSTAL study, patients with metastatic colorectal cancer (mCRC) were treated with cetuximab plus FOLFIRI or FOLFIRI alone until disease progression, unacceptable toxic effects or withdrawal of consent. OBJECTIVE: To determine if stratified use of cetuximab based on genetic biomarker detection improves cost-effectiveness. METHODS: We used individual patient data from CRYSTAL to compare the cost-effectiveness, cost per life-year (LY) and cost per quality-adjusted LY (QALY) gained of cetuximab plus FOLFIRI versus FOLFIRI alone in three cohorts of patients with mCRC: all randomised patients (intent-to-treat; ITT), tumours with no detectable mutations in codons 12 and 13 of exon 2 of the KRAS protein (‘KRAS wt’) and no detectable mutations in exons 2, 3 and 4 of KRAS and exons 2, 3 and 4 of NRAS (‘RAS wt’). Survival analysis was conducted using RStudio, and a cost-utility model was modified to allow comparison of the three cohorts. RESULTS: The deterministic base-case ICER (cost per QALY gained) was £130,929 in the ITT, £72,053 in the KRAS wt and £44,185 in the RAS wt cohorts for cetuximab plus FOLFIRI compared with FOLFIRI alone. At a £50,000 willingness-to-pay threshold, cetuximab plus FOLFIRI has a 2.8, 20 and 63% probability of being cost-effective for the ITT, KRAS wt and RAS wt cohorts, respectively, versus FOLFIRI alone. CONCLUSION: Screening for mutations in both KRAS and NRAS may provide the most cost-effective approach to patient selection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-018-0395-5) contains supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6028886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-60288862018-07-23 Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work Harty, Gerard Jarrett, James Jofre-Bonet, Mireia Appl Health Econ Health Policy Original Research Article BACKGROUND: Therapies may be more efficacious when targeting a patient subpopulation with specific attributes, thereby enhancing the cost-effectiveness of treatment. In the CRYSTAL study, patients with metastatic colorectal cancer (mCRC) were treated with cetuximab plus FOLFIRI or FOLFIRI alone until disease progression, unacceptable toxic effects or withdrawal of consent. OBJECTIVE: To determine if stratified use of cetuximab based on genetic biomarker detection improves cost-effectiveness. METHODS: We used individual patient data from CRYSTAL to compare the cost-effectiveness, cost per life-year (LY) and cost per quality-adjusted LY (QALY) gained of cetuximab plus FOLFIRI versus FOLFIRI alone in three cohorts of patients with mCRC: all randomised patients (intent-to-treat; ITT), tumours with no detectable mutations in codons 12 and 13 of exon 2 of the KRAS protein (‘KRAS wt’) and no detectable mutations in exons 2, 3 and 4 of KRAS and exons 2, 3 and 4 of NRAS (‘RAS wt’). Survival analysis was conducted using RStudio, and a cost-utility model was modified to allow comparison of the three cohorts. RESULTS: The deterministic base-case ICER (cost per QALY gained) was £130,929 in the ITT, £72,053 in the KRAS wt and £44,185 in the RAS wt cohorts for cetuximab plus FOLFIRI compared with FOLFIRI alone. At a £50,000 willingness-to-pay threshold, cetuximab plus FOLFIRI has a 2.8, 20 and 63% probability of being cost-effective for the ITT, KRAS wt and RAS wt cohorts, respectively, versus FOLFIRI alone. CONCLUSION: Screening for mutations in both KRAS and NRAS may provide the most cost-effective approach to patient selection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40258-018-0395-5) contains supplementary material, which is available to authorised users. Springer International Publishing 2018-06-09 2018 /pmc/articles/PMC6028886/ /pubmed/29948926 http://dx.doi.org/10.1007/s40258-018-0395-5 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Harty, Gerard Jarrett, James Jofre-Bonet, Mireia Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title | Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title_full | Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title_fullStr | Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title_full_unstemmed | Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title_short | Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
title_sort | consequences of biomarker analysis on the cost-effectiveness of cetuximab in combination with folfiri as a first-line treatment of metastatic colorectal cancer: personalised medicine at work |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028886/ https://www.ncbi.nlm.nih.gov/pubmed/29948926 http://dx.doi.org/10.1007/s40258-018-0395-5 |
work_keys_str_mv | AT hartygerard consequencesofbiomarkeranalysisonthecosteffectivenessofcetuximabincombinationwithfolfiriasafirstlinetreatmentofmetastaticcolorectalcancerpersonalisedmedicineatwork AT jarrettjames consequencesofbiomarkeranalysisonthecosteffectivenessofcetuximabincombinationwithfolfiriasafirstlinetreatmentofmetastaticcolorectalcancerpersonalisedmedicineatwork AT jofrebonetmireia consequencesofbiomarkeranalysisonthecosteffectivenessofcetuximabincombinationwithfolfiriasafirstlinetreatmentofmetastaticcolorectalcancerpersonalisedmedicineatwork |